Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02969018

Enrollment

212

Registered

2016-11-21

Start date

2016-12-31

Completion date

2018-03-31

Last updated

2019-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Plaque Psoriasis

Keywords

plaque psoriasis

Brief summary

The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.

Interventions

DRUGPF-06700841

OTHERPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Have had a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline/Day 1 (prior to first dose of study drug) * Have a PASI score of 12 or greater AND a PGA score of 3 (moderate) or 4 (severe) at Baseline/Day 1 (prior to first dose of study drug) * Have plaque-type psoriasis covering at least 10% of total body surface area (BSA) at Baseline/Day 1 (prior to first dose of study drug) * Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment)

Exclusion criteria

* Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed * Have evidence of skin conditions (eg, eczema) at the time of screening or baseline visit that would interfere with the evaluation of psoriasis * Cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA) * Have previously been treated with Secukinumab (Cosentyx), and Ixekizumab (Taltz). * Have taken Apremilast (Otezla) within 3 months of first dose of study drug. * Have undergone treatment with tofacitinib within 3 months of first dose.

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12	Baseline (Day 1 pre-dose), Week 12	The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Secondary

Measure	Time frame	Description
Change From Baseline in PASI Scores at Week 4 by Induction Dose	Baseline (Day 1 pre-dose), Week 4	Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Weeks 1, 2, 4, 6, 8, 10, 14, 16	A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 14, 16	The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12	Week 12	A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.
Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs	From first dose of study treatment (Day 1) up to Week 20	The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).
Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Baseline (Day 1 pre-dose), Weeks 4 and 12	Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.
Number of Participants With Any Post-Baseline Laboratory Test Abnormalities	From first dose of study treatment (Day 1) up to Week 16	Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time \[PT\], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).
Number of Participants With Post-Baseline Vital Sign Abnormalities	From first dose of study treatment (Day 1) up to Week 16	Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) \<50 mmHg; 3) sitting pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (\>=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP \>=30 mmHg.
Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	From first dose of study treatment (Day 1) up to Week 16	ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): \>=140 milliseconds (msec), \>=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): \>=300 msec, \>=25% change when baseline is \> 200 msec or \>=50% change when baseline is less than or equal to (\<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of \>=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; a change from baseline of 30 to \<60 msec or \>=60 msec.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	From first dose of study treatment (Day 1) up to Week 20	An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.

Countries

Canada, Poland, United States

Participant flow

Participants by arm

Arm	Count
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 30 mg QD (blinded tablets).	25
PF-06700841 60 mg QD Followed by 10 mg QD Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	29
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW) Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	26
PF-06700841 60 mg QD Followed by Placebo Participants received 4-week induction of PF-06700841 60 mg QD (blinded tablets) followed by 8-week maintenance of matching placebo QD (blinded tablets).	25
PF-06700841 30 mg QD Participants received 12 weeks of blinded PF-06700841 30 mg QD tablets.	29
PF-06700841 30 mg QD Followed by 10 mg QD Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 10 mg QD (blinded tablets).	25
PF-06700841 30 mg QD Followed by 100 mg QW Participants received 4-week induction of PF-06700841 30 mg QD (blinded tablets) followed by 8-week maintenance of PF-06700841 100 mg QW (blinded tablets).	30
Placebo Participants received 12 weeks of blinded matching placebo QD tablets.	23
Total	212

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006	FG007
Overall Study	Adverse Event	2	4	1	2	0	1	2	0
Overall Study	Lack of Efficacy	0	1	0	0	1	1	1	1
Overall Study	Lost to Follow-up	1	2	2	0	1	1	0	1
Overall Study	No Longer Meets Eligibility Criteria	0	0	0	0	0	0	1	0
Overall Study	Non-Compliance With Study Drug	1	0	0	0	0	0	0	0
Overall Study	Other	0	0	0	1	0	0	0	2
Overall Study	Pregnancy	0	0	0	0	0	1	0	0
Overall Study	Protocol Violation	0	0	1	1	0	0	0	0
Overall Study	Withdrawal by Subject	0	1	2	1	0	4	4	3

Baseline characteristics

Characteristic	PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	PF-06700841 60 mg QD Followed by 10 mg QD	PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	PF-06700841 60 mg QD Followed by Placebo	PF-06700841 30 mg QD	PF-06700841 30 mg QD Followed by 10 mg QD	PF-06700841 30 mg QD Followed by 100 mg QW	Placebo	Total
Age, Continuous	49.0 years STANDARD_DEVIATION 14.69	44.6 years STANDARD_DEVIATION 13.71	45.5 years STANDARD_DEVIATION 12.93	48.4 years STANDARD_DEVIATION 15.47	44.2 years STANDARD_DEVIATION 10.92	44.0 years STANDARD_DEVIATION 11.56	43.2 years STANDARD_DEVIATION 12.28	50.3 years STANDARD_DEVIATION 12.23	46.0 years STANDARD_DEVIATION 13.04
Age, Customized 18-44 Years	8 Participants	14 Participants	10 Participants	8 Participants	14 Participants	12 Participants	14 Participants	8 Participants	88 Participants
Age, Customized 45-64 Years	14 Participants	13 Participants	14 Participants	13 Participants	14 Participants	13 Participants	16 Participants	12 Participants	109 Participants
Age, Customized >=65 Years	3 Participants	2 Participants	2 Participants	4 Participants	1 Participants	0 Participants	0 Participants	3 Participants	15 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	4 Participants	4 Participants	4 Participants	2 Participants	6 Participants	5 Participants	4 Participants	4 Participants	33 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	21 Participants	25 Participants	22 Participants	23 Participants	23 Participants	20 Participants	26 Participants	19 Participants	179 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	3 Participants
Race/Ethnicity, Customized Asian	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	2 Participants	0 Participants	4 Participants
Race/Ethnicity, Customized Black or African American	3 Participants	0 Participants	3 Participants	0 Participants	1 Participants	1 Participants	1 Participants	2 Participants	11 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants	2 Participants
Race/Ethnicity, Customized Other	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	1 Participants	3 Participants
Race/Ethnicity, Customized White	22 Participants	27 Participants	23 Participants	24 Participants	27 Participants	22 Participants	25 Participants	19 Participants	189 Participants
Sex: Female, Male Female	9 Participants	8 Participants	14 Participants	4 Participants	10 Participants	8 Participants	7 Participants	4 Participants	64 Participants
Sex: Female, Male Male	16 Participants	21 Participants	12 Participants	21 Participants	19 Participants	17 Participants	23 Participants	19 Participants	148 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk
deaths Total, all-cause mortality	1 / 25	0 / 29	0 / 26	0 / 25	0 / 29	0 / 25	0 / 30	0 / 23
other Total, other adverse events	11 / 25	14 / 29	13 / 26	13 / 25	13 / 29	12 / 25	16 / 30	9 / 23
serious Total, serious adverse events	2 / 25	1 / 29	1 / 26	1 / 25	0 / 29	0 / 25	0 / 30	0 / 23

Outcome results

Primary

Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. In each area, the sum of the severity rating scores for erythema, induration and scaling is multiplied by the score representing the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of the numbers obtained for each of the four body areas is the PASI. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame: Baseline (Day 1 pre-dose), Week 12

Population: All randomized participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data for Week 12.

Arm	Measure	Value (LEAST_SQUARES_MEAN)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12	-15.85 units on a scale
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12	-10.56 units on a scale
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12	-14.28 units on a scale
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12	-10.14 units on a scale
PF-06700841 30 mg QD	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12	-17.28 units on a scale
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12	-13.27 units on a scale
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12	-11.88 units on a scale
Placebo	Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12	-7.21 units on a scale

p-value: 0.000590% CI: [-12.33, -4.95]Mixed Models Analysis

p-value: 0.096390% CI: [-6.99, 0.3]Mixed Models Analysis

p-value: 0.004690% CI: [-10.76, -3.37]Mixed Models Analysis

p-value: 0.096390% CI: [-6.63, 0.77]Mixed Models Analysis

p-value: <0.000190% CI: [-13.63, -6.51]Mixed Models Analysis

p-value: 0.015890% CI: [-9.79, -2.33]Mixed Models Analysis

p-value: 0.048890% CI: [-8.24, -1.09]Mixed Models Analysis

Secondary

Change From Baseline in Blood Lipid Level at Weeks 4 and 12

Lipid panel included low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, total cholesterol, and triglycerides.

Time frame: Baseline (Day 1 pre-dose), Weeks 4 and 12

Population: Number of participants analyzed represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo). Number analyzed represents all participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had data for each specified category.

Arm	Measure	Group	Value (MEAN)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 12	19.50 milligram per deciliter (mg/dL)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 4	12.09 milligram per deciliter (mg/dL)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 4	34.74 milligram per deciliter (mg/dL)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 4	34.39 milligram per deciliter (mg/dL)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 12	27.86 milligram per deciliter (mg/dL)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 4	15.91 milligram per deciliter (mg/dL)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 12	8.71 milligram per deciliter (mg/dL)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 12	5.00 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 4	29.46 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 12	48.33 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 4	9.14 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 12	6.00 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 4	11.27 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 4	29.68 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 12	15.67 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 12	5.48 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 4	8.04 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 12	2.48 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 4	31.32 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 12	-0.74 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 12	-1.86 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 4	10.92 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 12	-85.00 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 4	15.00 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 4	8.58 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 12	7.05 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 12	6.85 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 4	8.92 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 12	-0.24 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 12	2.67 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 4	15.88 milligram per deciliter (mg/dL)
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 4	26.33 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 12	-18.96 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 4	8.96 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 12	14.10 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 4	-65.11 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 12	20.37 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 12	4.74 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 4	15.14 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 4	6.36 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 4	-2.21 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 12	6.32 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 12	-5.33 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 4	6.76 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 12	4.37 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 4	10.36 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 12	0.68 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 4	19.60 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 4	7.60 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 4	14.00 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 12	2.88 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 4	9.39 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 12	3.95 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 12	-67.79 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 4	-59.75 milligram per deciliter (mg/dL)
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 12	4.33 milligram per deciliter (mg/dL)
Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 4	-4.42 milligram per deciliter (mg/dL)
Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 4	-6.28 milligram per deciliter (mg/dL)
Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	LDL Cholesterol, Week 12	-4.00 milligram per deciliter (mg/dL)
Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 4	0.00 milligram per deciliter (mg/dL)
Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	HDL Cholesterol, Week 12	-2.73 milligram per deciliter (mg/dL)
Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 12	1.87 milligram per deciliter (mg/dL)
Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Total Cholesterol, Week 12	-6.40 milligram per deciliter (mg/dL)
Placebo	Change From Baseline in Blood Lipid Level at Weeks 4 and 12	Triglycerides, Week 4	15.26 milligram per deciliter (mg/dL)

Secondary

Change From Baseline in PASI Scores at Week 4 by Induction Dose

Change from baseline in PASI scores at Week 4 was presented by induction dose (ie, PF-06700841 60 mg QD, 30 mg QD, and placebo). The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame: Baseline (Day 1 pre-dose), Week 4

Population: All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had observed PASI data at Week 4.

Arm	Measure	Value (LEAST_SQUARES_MEAN)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in PASI Scores at Week 4 by Induction Dose	-13.17 units on a scale
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Week 4 by Induction Dose	-12.16 units on a scale
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in PASI Scores at Week 4 by Induction Dose	-4.17 units on a scale

p-value: <0.000190% CI: [-11.43, -6.57]Mixed Models Analysis

p-value: <0.000190% CI: [-10.48, -5.51]Mixed Models Analysis

Secondary

Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16

The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 14, 16

Arm	Measure	Group	Value (MEAN)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	-16.54 units on a scale
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	-5.74 units on a scale
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	-12.85 units on a scale
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	-9.44 units on a scale
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	-14.16 units on a scale
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	-15.00 units on a scale
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	-15.94 units on a scale
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	-15.47 units on a scale
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	-4.60 units on a scale
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	-8.11 units on a scale
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	-8.35 units on a scale
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	-12.19 units on a scale
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	-6.59 units on a scale
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	-12.12 units on a scale
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	-9.89 units on a scale
PF-06700841 60 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	-11.09 units on a scale
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	-15.52 units on a scale
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	-10.79 units on a scale
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	-13.00 units on a scale
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	-14.11 units on a scale
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	-13.31 units on a scale
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	-15.00 units on a scale
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	-5.85 units on a scale
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	-14.97 units on a scale
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	-9.45 units on a scale
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	-7.83 units on a scale
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	-9.49 units on a scale
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	-12.87 units on a scale
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	-11.64 units on a scale
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	-5.37 units on a scale
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	-13.85 units on a scale
PF-06700841 60 mg QD Followed by Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	-13.91 units on a scale
PF-06700841 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	-3.97 units on a scale
PF-06700841 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	-16.14 units on a scale
PF-06700841 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	-15.82 units on a scale
PF-06700841 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	-14.38 units on a scale
PF-06700841 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	-14.30 units on a scale
PF-06700841 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	-7.86 units on a scale
PF-06700841 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	-11.72 units on a scale
PF-06700841 30 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	-16.65 units on a scale
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	-14.33 units on a scale
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	-4.41 units on a scale
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	-7.79 units on a scale
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	-12.88 units on a scale
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	-14.27 units on a scale
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	-14.98 units on a scale
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	-10.44 units on a scale
PF-06700841 30 mg QD Followed by 10 mg QD	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	-9.62 units on a scale
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	-13.83 units on a scale
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	-13.06 units on a scale
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	-7.93 units on a scale
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	-9.13 units on a scale
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	-3.46 units on a scale
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	-11.03 units on a scale
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	-12.97 units on a scale
PF-06700841 30 mg QD Followed by 100 mg QW	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	-14.17 units on a scale
Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	-6.78 units on a scale
Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	-5.52 units on a scale
Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	-2.28 units on a scale
Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	-6.98 units on a scale
Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	-4.02 units on a scale
Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	-1.35 units on a scale
Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	-6.76 units on a scale
Placebo	Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	-6.56 units on a scale

Secondary

Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs

The number of participants who discontinued from the study due to treatment-emergent AEs is presented. Note for data reported under this Outcome Measure: Per sponsor reporting standard, pregnancy was counted as AE for AE data tables while it was counted separately in the disposition data table (Participant Flow Module).

Time frame: From first dose of study treatment (Day 1) up to Week 20

Population: All participants who received at least 1 dose of investigational product (PF-06700841 or placebo).

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs	2 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs	4 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs	1 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs	2 Participants
PF-06700841 30 mg QD	Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs	2 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs	2 Participants
Placebo	Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs	0 Participants

Secondary

Number of Participants With Any Post-Baseline Laboratory Test Abnormalities

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time \[PT\], PT/international normalized ratio; chemistry (total bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, protein, albumin, urea nitrogen, creatinine, urate, total cholesterol, LDL and HDL cholesterol, triglycerides, calcium, sodium, potassium, chloride, bicarbonate, glucose, creatine kinase, Cystatin C, glomerular filtration rate; urinalysis (pH, urine glucose, ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, hyaline casts, bacteria, choriogonadotropin beta).

Time frame: From first dose of study treatment (Day 1) up to Week 16

Population: All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline laboratory data.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Any Post-Baseline Laboratory Test Abnormalities	17 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Any Post-Baseline Laboratory Test Abnormalities	20 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Any Post-Baseline Laboratory Test Abnormalities	20 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Any Post-Baseline Laboratory Test Abnormalities	16 Participants
PF-06700841 30 mg QD	Number of Participants With Any Post-Baseline Laboratory Test Abnormalities	21 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Any Post-Baseline Laboratory Test Abnormalities	20 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Any Post-Baseline Laboratory Test Abnormalities	18 Participants
Placebo	Number of Participants With Any Post-Baseline Laboratory Test Abnormalities	11 Participants

Secondary

Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities

ECG categorical summarization criteria: 1) QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): \>=140 milliseconds (msec), \>=50% change from baseline; 2) PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): \>=300 msec, \>=25% change when baseline is \> 200 msec or \>=50% change when baseline is less than or equal to (\<=) 200 msec; 3) QT interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole): absolute value of \>=500 msec; 4) QTc interval (QT corrected for heart rate): absolute value of 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; a change from baseline of 30 to \<60 msec or \>=60 msec.

Time frame: From first dose of study treatment (Day 1) up to Week 16

Population: All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline ECG data.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=500 msec	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	PR interval >=300 msec	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in QRS duration >=50%	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=60 msec	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QT interval >=500 msec	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=450 to <480 msec	6 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QRS duration >=140 msec	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=480 to <500 msec	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in PR interval >=25/50%	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=30 to <60 msec	2 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=60 msec	0 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QT interval >=500 msec	0 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	PR interval >=300 msec	0 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=500 msec	0 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in PR interval >=25/50%	0 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=30 to <60 msec	0 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=480 to <500 msec	0 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QRS duration >=140 msec	1 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=450 to <480 msec	1 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in QRS duration >=50%	0 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QRS duration >=140 msec	0 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=480 to <500 msec	1 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=500 msec	0 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QT interval >=500 msec	0 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	PR interval >=300 msec	1 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in PR interval >=25/50%	0 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=30 to <60 msec	2 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=450 to <480 msec	2 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=60 msec	2 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in QRS duration >=50%	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=480 to <500 msec	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in PR interval >=25/50%	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QT interval >=500 msec	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=60 msec	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in QRS duration >=50%	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QRS duration >=140 msec	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	PR interval >=300 msec	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=450 to <480 msec	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=500 msec	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=30 to <60 msec	1 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=30 to <60 msec	3 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=60 msec	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	PR interval >=300 msec	1 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in PR interval >=25/50%	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QRS duration >=140 msec	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in QRS duration >=50%	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QT interval >=500 msec	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=450 to <480 msec	1 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=480 to <500 msec	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=500 msec	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QT interval >=500 msec	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in QRS duration >=50%	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QRS duration >=140 msec	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=450 to <480 msec	1 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in PR interval >=25/50%	1 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=30 to <60 msec	3 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=480 to <500 msec	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	PR interval >=300 msec	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=500 msec	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=60 msec	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=60 msec	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in PR interval >=25/50%	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=480 to <500 msec	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	PR interval >=300 msec	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QRS duration >=140 msec	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in QRS duration >=50%	1 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=30 to <60 msec	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=500 msec	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=450 to <480 msec	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QT interval >=500 msec	0 Participants
Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=450 to <480 msec	1 Participants
Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=500 msec	0 Participants
Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	PR interval >=300 msec	0 Participants
Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in QRS duration >=50%	0 Participants
Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=60 msec	1 Participants
Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QT interval >=500 msec	0 Participants
Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc >=480 to <500 msec	1 Participants
Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QRS duration >=140 msec	0 Participants
Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	QTc change >=30 to <60 msec	1 Participants
Placebo	Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities	%Change in PR interval >=25/50%	0 Participants

Secondary

Number of Participants With Post-Baseline Vital Sign Abnormalities

Vital signs categorical summarization criteria: 1) sitting systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) sitting diastolic blood pressure (DBP) \<50 mmHg; 3) sitting pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in sitting DBP greater than or equal to (\>=) 20 mmHg; 5) change from baseline (increase or decrease) in sitting SBP \>=30 mmHg.

Time frame: From first dose of study treatment (Day 1) up to Week 16

Population: All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) and had post-baseline vital signs data.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP decrease >=30 mm Hg	2 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate <40 bpm	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate >120 bpm	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP increase >=20 mm Hg	1 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP <90 mm Hg	1 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP <50 mm Hg	0 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP decrease >=20 mm Hg	3 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP increase >=30 mm Hg	1 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP increase >=20 mm Hg	1 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP <50 mm Hg	0 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP decrease >=30 mm Hg	2 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP <90 mm Hg	1 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate >120 bpm	0 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate <40 bpm	0 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP increase >=30 mm Hg	3 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP decrease >=20 mm Hg	0 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP increase >=30 mm Hg	2 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP <90 mm Hg	0 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate <40 bpm	0 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP decrease >=30 mm Hg	1 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate >120 bpm	0 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP increase >=20 mm Hg	3 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP decrease >=20 mm Hg	2 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP <50 mm Hg	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP <50 mm Hg	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate <40 bpm	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP increase >=20 mm Hg	2 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate >120 bpm	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP decrease >=20 mm Hg	2 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP <90 mm Hg	0 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP increase >=30 mm Hg	1 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP decrease >=30 mm Hg	2 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP <90 mm Hg	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP decrease >=20 mm Hg	1 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP increase >=30 mm Hg	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP increase >=20 mm Hg	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate >120 bpm	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP <50 mm Hg	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate <40 bpm	0 Participants
PF-06700841 30 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP decrease >=30 mm Hg	1 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP <90 mm Hg	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP <50 mm Hg	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate >120 bpm	1 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP increase >=20 mm Hg	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP decrease >=30 mm Hg	3 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP decrease >=20 mm Hg	2 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP increase >=30 mm Hg	1 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate <40 bpm	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP decrease >=30 mm Hg	2 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP <50 mm Hg	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP increase >=20 mm Hg	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP decrease >=20 mm Hg	2 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP <90 mm Hg	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP increase >=30 mm Hg	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate <40 bpm	0 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate >120 bpm	0 Participants
Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate <40 bpm	0 Participants
Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP increase >=30 mm Hg	0 Participants
Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP <90 mm Hg	0 Participants
Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP decrease >=20 mm Hg	1 Participants
Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP increase >=20 mm Hg	0 Participants
Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting DBP <50 mm Hg	0 Participants
Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting SBP decrease >=30 mm Hg	1 Participants
Placebo	Number of Participants With Post-Baseline Vital Sign Abnormalities	Sitting pulse rate >120 bpm	0 Participants

Secondary

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or an important medical event. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.

Time frame: From first dose of study treatment (Day 1) up to Week 20

Population: All participants who received at least 1 dose of investigational product (PF-06700841 or placebo).

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent SAEs	2 Participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent AEs	19 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent SAEs	1 Participants
PF-06700841 60 mg QD Followed by 10 mg QD	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent AEs	21 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent AEs	18 Participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent SAEs	1 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent AEs	18 Participants
PF-06700841 60 mg QD Followed by Placebo	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent SAEs	1 Participants
PF-06700841 30 mg QD	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent AEs	21 Participants
PF-06700841 30 mg QD	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent SAEs	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent SAEs	0 Participants
PF-06700841 30 mg QD Followed by 10 mg QD	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent AEs	16 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent AEs	23 Participants
PF-06700841 30 mg QD Followed by 100 mg QW	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent SAEs	0 Participants
Placebo	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent AEs	13 Participants
Placebo	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Treatment-emergent SAEs	0 Participants

Secondary

Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

A PASI50 response is a 50% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

Population: All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.

Arm	Measure	Group	Value (NUMBER)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	44.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	72.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	60.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	60.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	64.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	68.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	72.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	68.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	12.0 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	62.1 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	55.2 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	34.5 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	44.8 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	37.9 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	13.8 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	44.8 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	69.0 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	44.8 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	73.1 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	69.2 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	19.2 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	73.1 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	73.1 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	61.5 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	53.8 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	69.2 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	46.2 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	52.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	20.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	32.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	68.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	68.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	48.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	52.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	48.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	40.0 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	86.2 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	82.8 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	41.4 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	89.7 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	10.3 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	89.7 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	86.2 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	69.0 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	79.3 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	48.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	56.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	60.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	48.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	20.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	40.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	36.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	8.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	60.0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	36.7 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	56.7 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	63.3 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	53.3 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	3.3 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	33.3 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	36.7 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	66.7 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	63.3 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	17.4 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	21.7 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	0 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	26.1 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	17.4 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	0 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	21.7 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	26.1 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	13.0 percentage of participants

Secondary

Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12

A PASI75 response is a 75% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame: Week 12

Population: All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data at Week 12 after non-responder imputation applied.

Arm	Measure	Value (NUMBER)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12	60.0 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12	24.1 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12	57.7 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12	24.0 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12	86.2 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12	24.0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12	36.7 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12	13.0 percentage of participants

90% CI: [2.95, 33.87]

90% CI: [0.61, 7.36]

90% CI: [2.71, 30.48]

90% CI: [0.59, 7.55]

90% CI: [10.8, 160.68]

90% CI: [0.59, 7.55]

90% CI: [1.17, 12.74]

Secondary

Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

A PASI90 response is a 90% or greater reduction from baseline in PASI score. The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

Population: All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.

Arm	Measure	Group	Value (NUMBER)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	28.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	16.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	24.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	20.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	36.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	12.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	28.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	0 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	20.7 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	17.2 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	13.8 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	20.7 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	3.4 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	3.4 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	3.4 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	13.8 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	17.2 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	0 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	42.3 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	26.9 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	11.5 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	26.9 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	7.7 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	15.4 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	30.8 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	26.9 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	4.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	8.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	16.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	8.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	12.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	8.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	8.0 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	37.9 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	34.5 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	0 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	34.5 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	0 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	51.7 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	6.9 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	24.1 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	27.6 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	8.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	8.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	8.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	4.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	8.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	8.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	4.0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	10.0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	13.3 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	10.0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	3.3 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	20.0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	16.7 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	13.3 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	0 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	0 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	4.3 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	0 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	4.3 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	0 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	0 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	4.3 percentage of participants
Placebo	Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	4.3 percentage of participants

Secondary

Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16

Time frame: Weeks 1, 2, 4, 6, 8, 10, 14, 16

Population: All participants who received at least 1 dose of investigational product (PF-06700841 or placebo) with PASI data for each specified time point after non-responder imputation applied.

Arm	Measure	Group	Value (NUMBER)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	8.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	36.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	48.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	48.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	44.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	24.0 percentage of participants
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	60.0 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	6.9 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	37.9 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	10.3 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	13.8 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	17.2 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	41.4 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	41.4 percentage of participants
PF-06700841 60 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	24.1 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	30.8 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	34.6 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	61.5 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	61.5 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	7.7 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	65.4 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	65.4 percentage of participants
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	26.9 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	16.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	20.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	4.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	32.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	36.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	32.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	36.0 percentage of participants
PF-06700841 60 mg QD Followed by Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	12.0 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	51.7 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	58.6 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	27.6 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	3.4 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	65.5 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	0 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	72.4 percentage of participants
PF-06700841 30 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	75.9 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	28.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	8.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	28.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	12.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	24.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	20.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	4.0 percentage of participants
PF-06700841 30 mg QD Followed by 10 mg QD	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	16.0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	36.7 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	16.7 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	46.7 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	26.7 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	16.7 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	0 percentage of participants
PF-06700841 30 mg QD Followed by 100 mg QW	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	40.0 percentage of participants
Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 16	8.7 percentage of participants
Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 1	0 percentage of participants
Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 2	0 percentage of participants
Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 4	0 percentage of participants
Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 6	8.7 percentage of participants
Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 8	8.7 percentage of participants
Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 10	13.0 percentage of participants
Placebo	Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16	Week 14	8.7 percentage of participants

Secondary

Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

The PASI score can vary in increments of 0.1 units from 0.0 to 72.0, with higher scores representing increasing severity of psoriasis.

Time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

Arm	Measure	Group	Value (MEAN)
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	-57.28 percent change
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	-57.16 percent change
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	-26.70 percent change
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	-70.72 percent change
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	-70.11 percent change
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	-64.15 percent change
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	-43.66 percent change
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	-71.94 percent change
PF-06700841 60 mg Once Daily (QD) Followed by 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	-66.07 percent change
PF-06700841 60 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	-38.48 percent change
PF-06700841 60 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	-24.66 percent change
PF-06700841 60 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	-63.02 percent change
PF-06700841 60 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	-58.52 percent change
PF-06700841 60 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	-62.25 percent change
PF-06700841 60 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	-63.31 percent change
PF-06700841 60 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	-57.55 percent change
PF-06700841 60 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	-47.87 percent change
PF-06700841 60 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	-44.17 percent change
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	-63.20 percent change
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	-74.42 percent change
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	-77.05 percent change
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	-60.56 percent change
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	-54.27 percent change
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	-72.41 percent change
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	-75.96 percent change
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	-30.25 percent change
PF-06700841 60 mg QD Followed by 100 mg Once Weekly (QW)	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	-78.46 percent change
PF-06700841 60 mg QD Followed by Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	-59.88 percent change
PF-06700841 60 mg QD Followed by Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	-23.33 percent change
PF-06700841 60 mg QD Followed by Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	-53.81 percent change
PF-06700841 60 mg QD Followed by Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	-42.58 percent change
PF-06700841 60 mg QD Followed by Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	-51.49 percent change
PF-06700841 60 mg QD Followed by Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	-44.30 percent change
PF-06700841 60 mg QD Followed by Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	-65.06 percent change
PF-06700841 60 mg QD Followed by Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	-64.71 percent change
PF-06700841 60 mg QD Followed by Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	-36.63 percent change
PF-06700841 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	-83.39 percent change
PF-06700841 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	-40.89 percent change
PF-06700841 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	-73.91 percent change
PF-06700841 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	-84.82 percent change
PF-06700841 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	-81.04 percent change
PF-06700841 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	-20.92 percent change
PF-06700841 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	-88.68 percent change
PF-06700841 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	-60.76 percent change
PF-06700841 30 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	-74.18 percent change
PF-06700841 30 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	-47.84 percent change
PF-06700841 30 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	-17.50 percent change
PF-06700841 30 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	-32.46 percent change
PF-06700841 30 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	-53.93 percent change
PF-06700841 30 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	-58.57 percent change
PF-06700841 30 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	-58.32 percent change
PF-06700841 30 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	-61.23 percent change
PF-06700841 30 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	-57.81 percent change
PF-06700841 30 mg QD Followed by 10 mg QD	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	-44.58 percent change
PF-06700841 30 mg QD Followed by 100 mg QW	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	-57.24 percent change
PF-06700841 30 mg QD Followed by 100 mg QW	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	-58.57 percent change
PF-06700841 30 mg QD Followed by 100 mg QW	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	-61.38 percent change
PF-06700841 30 mg QD Followed by 100 mg QW	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	-63.17 percent change
PF-06700841 30 mg QD Followed by 100 mg QW	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	-58.99 percent change
PF-06700841 30 mg QD Followed by 100 mg QW	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	-47.52 percent change
PF-06700841 30 mg QD Followed by 100 mg QW	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	-35.89 percent change
PF-06700841 30 mg QD Followed by 100 mg QW	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	-15.42 percent change
PF-06700841 30 mg QD Followed by 100 mg QW	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	-42.29 percent change
Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 10	-39.68 percent change
Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 14	-39.48 percent change
Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 12	-40.27 percent change
Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 8	-37.76 percent change
Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 2	-12.81 percent change
Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 6	-33.49 percent change
Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 16	-38.79 percent change
Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 4	-25.17 percent change
Placebo	Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16	Week 1	-6.90 percent change

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12

Change From Baseline in Blood Lipid Level at Weeks 4 and 12

Change From Baseline in PASI Scores at Week 4 by Induction Dose

Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 14, 16

Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs

Number of Participants With Any Post-Baseline Laboratory Test Abnormalities

Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities

Number of Participants With Post-Baseline Vital Sign Abnormalities

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI50) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12

Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI90) Response at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16

Percentage of Participants Achieving PASI75 Responses at Weeks 1, 2, 4, 6, 8, 10, 14, 16

Percent Change From Baseline in PASI Scores at Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16